Prepared by Dr. Sofia Chen, CFA, Senior Equity Strategist | Reviewed by David Miller, Lead Editor | Report ID: IGEMINI-0CA9BC32-20260531 | Data as of 2026-05-31
Executive Summary: Our multi-factor model assigns manulife stock tsx a Cautiously Constructive outlook for the next quarter. Key drivers include a P/E of 16.15x, 16.3% revenue expansion, and an RSI of 35 suggesting a neutral-bullish phase. We define critical support at $1506.6 and resistance at $1841.4.
Rating: Buy | Target Price: $2343.6 | Next Earnings: Jun 28
Download Full PDF Report
Bollinger Bands contracted to the 15th percentile, signaling a breakout. A close above $1925.1 would be bullish.
On-chain money flow shows 22%% increase in smart money index, reinforcing the technical setup.
With a market cap of $13.51B, manulife stock tsx operates in Technology. P/E of 16.15x is backed by 16.3% growth.
EPS of $103.65 reveals high earnings quality. DuPont analysis highlights capital efficiency as the key ROE driver.
Beta of 1.07 suggests manulife stock tsx is {beta_desc} volatile than the market, influencing hedging strategies.
Short float at 5.6% is below the sector average, reducing squeeze risk. Institutional ownership is 74%.
| Metric | Value | Sector Avg |
|---|---|---|
| Last Price | $1674 | $1590.3 |
| Market Cap | $13.51B | $13.51B |
| P/E Ratio | 16.15x | 13.7x |
| EPS (TTM) | $103.65 | $93.29 |
| Dividend Yield | 5.31% | 3.7% |
| Revenue Growth | 16.3% | 9.8% |
| Target Price | $2343.6 | - |
| Beta | 1.07 | 1.00 |